Finding new uses for existing drugs to treat a rare bleeding disorder.
Official title: Repurposing drugs to treat Hereditary Hemorrhagic Telangiectasia: identification using a vascularized HHT on-a-chip microphysiological system platform
Funded at University of California-Irvine · NIH-11038808 · Data updated 2026-11-12
This study is looking for new ways to help people with Hereditary Hemorrhagic Telangiectasia (HHT) by testing existing medications to see if they can be used to treat the condition and improve blood vessel health.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | January 1, 2025 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $78,500 |
| NIH project number | 1R03NS141038-01 |
| Project ID | NIH-11038808 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Hereditary Hemorrhagic Telangiectasia, particularly those experiencing frequent bleeding episodes.
✕Less likely to help
Patients with other bleeding disorders or those not diagnosed with HHT may not benefit from this research.
What this research studies
This research focuses on Hereditary Hemorrhagic Telangiectasia (HHT), a rare condition that causes abnormal blood vessel formations leading to severe bleeding episodes. Using a specialized microphysiological system, researchers will screen a library of existing drugs to identify potential treatments that can be repurposed for HHT patients. The study aims to understand the genetic causes of HHT and how these affect blood vessel behavior, ultimately seeking to improve treatment options for those affected by this debilitating disease.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for patients suffering from HHT, reducing their bleeding episodes and improving their quality of life.
How similar studies have gone: While research on repurposing drugs for rare diseases is ongoing, this specific approach using a microphysiological system for HHT is relatively novel.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Hughes, Christopher C. W. — University of California-Irvine
- Study coordinator: Hughes, Christopher C. W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.